Quarterly report pursuant to Section 13 or 15(d)

Share-Based Compensation - Summary of Activity Under Share-Based Compensation Plans (Detail)

v3.24.1.u1
Share-Based Compensation - Summary of Activity Under Share-Based Compensation Plans (Detail) - USD ($)
$ / shares in Units, shares in Thousands, $ in Millions
 3 Months Ended 12 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Dec. 31, 2023
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Outstanding and nonvested, Beginning Balance, Number of Shares [1] 6,118    
Granted, Number of Shares 617    
Vested, Number of Shares (783)    
Forfeited, Number of Shares (108)    
Outstanding and nonvested, Ending Balance, Number of Shares [1] 5,844   6,118
Number of Shares, Expected to vest 4,713    
Outstanding and nonvested, Beginning Balance, Weighted Average Grant Date Fair Value Per Share [1] $ 20.76    
Granted, Weighted Average Grant Date Fair Value Per Share 8.07    
Vested, Weighted Average Grant Date Fair Value Per Share 39.04    
Forfeited, Weighted Average Grant Date Fair Value Per Share 17.89    
Outstanding and nonvested, Ending Balance, Weighted Average Grant Date Fair Value Per Share [1] 17.03   $ 20.76
Expected to vest, Ending Balance, Weighted Average Grant Date Fair Value Per Share $ 15.48    
SARs [Member]      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Number of Awards Outstanding, Beginning Balance [2] 4,340    
Granted, Number of Awards [3] 6,083    
Exercised, Number of Awards 0    
Forfeited, Number of Awards [4] (11)    
Number of Awards Outstanding, Ending Balance [2] 10,412   4,340
Number of Awards Exercisable, Ending Balance [5] 1,804    
Number of Awards Vested and expected to vest, Ending Balance [5] 7,035    
Weighted Average Exercise Price Per Award Outstanding, Beginning Balance [2] $ 19.85    
Granted, Weighted Average Exercise Price Per Award [3] 8.39    
Exercised, Weighted Average Exercise Price Per Award 0    
Forfeited, Weighted Average Exercise Price Per Award [4] 29.63    
Weighted Average Exercise Price Per Award Outstanding, Ending Balance [2] 13.14   $ 19.85
Exercisable, Weighted Average Exercise Price Per Award, Ending Balance [5] 26.11    
Weighted Average Exercise Price Per Award, Vested and expected to vest, Ending Balance [5] $ 15.19    
Weighted Average Remaining Contractual Term Outstanding [2] 7 years 4 months 24 days   6 years 4 months 24 days
Exercisable Weighted Average Remaining Contractual Term [4] 2 years 2 months 12 days    
Weighted Average Remaining Contractual Term, Vested and expected to vest [5] 7 years 4 months 24 days    
Aggregate Intrinsic Value Outstanding [2],[6] $ 10.1   $ 2.4
Exercisable, Aggregate Intrinsic Value [5],[6] 0.0    
Aggregate Intrinsic Value, Vested and expected to vest [5],[6] $ 3.8    
Granted, Weighted Average Grant Date Fair Value Per Share $ 4.43 $ 9.2  
[1] Includes 307,116 performance-based restricted stock units as of both March 31, 2024 and December 31, 2023, which represents the maximum amount that can vest.
[2] Includes 4.0 million and 0.6 million performance condition SARs as of March 31, 2024 and December 31, 2023, respectively.
[3] Includes 3.4 million performance condition SARs to a consultant
[4] Includes 0.6 million performance condition SARs
[5] Includes 0.9 million performance condition SARs
[6] The intrinsic value is the amount by which the current market value of the underlying stock exceeds the exercise price of the stock awards.